已收盘 11-20 16:00:00 美东时间
-2.650
-0.29%
Cramer called UiPath cheap but lacking catalysts, endorsed Karman and Affirm, warned on Onto and Nio, and favored Regeneron, Vertex and Amgen over Alnylam
11-20 20:52
The FDA approves Regeneron's Livsayis as the first siRNA therapy for adults with generalized myasthenia gravis, requiring four annual doses.
11-19 21:10
Regeneron reports Phase 2 PINNACLE trial data showing baloncibart reduces standing heart rate and improves symptoms in adults with POTS.
11-14 02:01
Regeneron reports positive trial data for ubamatamab in ovarian cancer and trevogrumab for muscle preservation during weight loss.
10-03 01:19
Kodiak Sciences announced positive data from its Phase 3 DAYBREAK study for its eye treatments Zenkuda and tabirafusp-ted.
09-28 22:05
The FDA approved Atebrioz by Mirum Pharmaceuticals and Incyte to treat FOP in patients aged 12 and older, reducing abnormal bone formation.
09-28 20:38
FDA approves Telix Pharmaceuticals' Pixclara, the first radiopharmaceutical brain cancer imaging drug for glioma PET scans.
09-14 21:50
Sanofi discontinued amlitelimab for atopic dermatitis after reviewing phase 3 efficacy and safety data, ending plans for regulatory filings.
07-25 02:10
Ocular outlines FDA-aligned AXPAXLI NDA plan for wet AMD by Q4 2026, revises SOL-R study design, and streamlines DR program.
06-17 22:55
Critical Metals (NASDAQ: CRML) shares are dropping Monday after it signed a binding Scheme Implementation Deed to acquire European Lithium.
05-19 01:54